CPP-Peptide Conjugates for Endothelial Apoptosis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for pharmacological treatments that effectively target microvascular injury, which is characterized by endothelial cell apoptosis and leads to conditions such as microhemorrhages and no-reflow phenomena, particularly in cardiac and cerebral pathologies, with existing treatments failing to provide adequate vasculoprotection.
Innovation Solution
The use of conjugates comprising specific peptides, such as Tat-DAXXp and Tat-FADDp, which interact with the FAS receptor to inhibit endothelial cell apoptosis, thereby reducing vascular damage and promoting vasculoprotection in conditions like myocardial infarction and hemorrhagic stroke.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for microvascular injury, then general cardiovascular support is provided, but specific vasculoprotection against endothelial apoptosis is not achieved
Solution Approach 1:
The patent employs FADD and DAXX proteins as intermediary molecules that mediate between the FAS death receptor signal and the apoptotic machinery. These intermediaries block the transmission of apoptotic signals in endothelial cells, preventing cell death while maintaining normal physiological functions. This intermediary approach provides specific vasculoprotection without interfering with other cardiovascular treatments.
Solution Approach 2:
The invention extracts and isolates the specific apoptotic signaling pathway (FAS-FADD-DAXX) from the complex cascade of cellular responses to microvascular injury. By targeting only this specific pathway with selective inhibitors, the treatment prevents endothelial apoptosis without affecting other cellular processes, achieving precise vasculoprotection while avoiding off-target effects.
2Object-affected harmful factors
If no specific anti-apoptotic therapy is applied, then treatment simplicity is maintained, but vascular damage and microhemorrhages worsen
Solution Approach 1:
The FADD and DAXX proteins serve as specific intermediaries in the apoptotic pathway, providing a targeted therapeutic approach. By administering these intermediary molecules or their mimetics, the treatment specifically blocks vascular damage without requiring complex multi-component therapies, thus reducing treatment complexity while improving vascular protection efficacy.
Solution Approach 2:
The invention changes the biochemical parameters of the apoptotic pathway by introducing exogenous FADD or DAXX proteins that alter the signaling dynamics. This parameter change approach transforms the irreversible apoptotic process into a protected state, reducing vascular damage through a single targeted intervention rather than multiple complex treatments.
3Object-generated harmful factors
If FAS-FADD dependent pathway is activated, then inflammatory response is induced, but endothelial cell death increases
Solution Approach 1:
The patent applies partial action by selectively modulating the FAS-FADD-DAXX pathway at a specific point in the signaling cascade. By introducing FADD or DAXX proteins in controlled amounts, the treatment achieves sufficient blockade of the apoptotic signal to prevent cell death and reduce inflammation, without completely suppressing the pathway's physiological functions, thus maintaining cell survival while controlling harmful inflammatory responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides demonstrate significant anti-apoptotic effects, reducing vascular complications and enhancing vascular density, thereby improving patient outcomes in conditions like myocardial infarction and hemorrhagic stroke.
Implementation Method 1
inhibitors of endothelial apoptosis for use in the treatment of a condition due to microvascular injury
Implementation Method 2
the FAS-FADD dependent pathway in vascular cells contributes to both caspase-dependent apoptosis and pro-inflammatory gene induction via NF-kB
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3A~3C
AI summary
The invention relates to a conjugate comprising a peptide having the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2, linked to a cell-penetrating peptide (CPP), for use in the treatment of a condition due to microvascular injury.